Roderick L Beijersbergen

List of Publications by Year
in descending order

88	18,148	53660 45	51492 86
papers	citations	h-index	g-index

97	97	97	23873
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. Nature Communications, 2022, 13, 2136.	5.8	4
2	Genetic and compound screens uncover factors modulating cancer cell response to indisulam. Life Science Alliance, 2022, 5, e202101348.	1.3	6
3	Impact of chromatin context on Cas9-induced DNA double-strand break repair pathway balance. Molecular Cell, 2021, 81, 2216-2230.e10.	4.5	106
4	Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen. Molecular Cancer Research, 2021, 19, 1613-1621.	1.5	6
5	A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. Scientific Reports, 2021, 11, 13683.	1.6	8
6	It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities. EBioMedicine, 2021, 69, 103448.	2.7	1
7	The Cancer SENESCopedia: A delineation of cancer cell senescence. Cell Reports, 2021, 36, 109441.	2.9	84
8	Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. Nature Communications, 2021, 12, 4360.	5.8	35
9	EGFR activation limits the response of liver cancer to lenvatinib. Nature, 2021, 595, 730-734.	13.7	183
10	Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer. Genome Medicine, 2021, 13, 166.	3.6	19
11	Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer. Cancers, 2021, 13, 6314.	1.7	3
12	CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut, 2020, 69, 727-736.	6.1	74
13	Highâ€throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells. European Journal of Immunology, 2020, 50, 73-85.	1.6	12
14	Old drugs with new tricks. Nature Cancer, 2020, 1, 153-155.	5.7	10
15	Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer. Cancer Research, 2019, 79, 2933-2946.	0.4	46
16	Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature, 2019, 574, 268-272.	13.7	249
17	TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth. ELife, 2019, 8, .	2.8	25
18	A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma. Cell Research, 2018, 28, 690-692.	5.7	46

#	Article	IF	Citations
19	PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma. Molecular Cancer Therapeutics, 2018, 17, 849-857.	1.9	28
20	Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities. Journal of Experimental Medicine, 2018, 215, 3115-3135.	4.2	29
21	A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers. Genome Medicine, 2018, 10, 90.	3.6	28
22	Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines. Cancer Research, 2018, 78, 4396-4410.	0.4	14
23	ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors. Oncogene, 2018, 37, 4611-4625.	2.6	72
24	Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. Cell Reports, 2018, 23, 3946-3959.e6.	2.9	245
25	Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer. Journal of Hepatology, 2018, 69, 1057-1065.	1.8	74
26	A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. European Urology, 2017, 71, 858-862.	0.9	59
27	High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer. Cell Reports, 2017, 21, 773-783.	2.9	136
28	Synthetic Lethality in Cancer Therapeutics. Annual Review of Cancer Biology, 2017, 1, 141-161.	2.3	36
29	Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R. Molecular Cancer Therapeutics, 2016, 15, 1545-1556.	1.9	30
30	A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell, 2016, 165, 317-330.	13.5	70
31	CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nature Biotechnology, 2016, 34, 631-633.	9.4	344
32	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. Clinical Cancer Research, 2016, 22, 5238-5248.	3.2	43
33	Pooled shRNA Screening in Mammalian Cells as a Functional Genomic Discovery Platform. Methods in Molecular Biology, 2016, 1470, 49-73.	0.4	6
34	Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer. Oncotarget, 2016, 7, 42859-42872.	0.8	10
35	An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation. Oncotarget, 2016, 7, 2596-2610.	0.8	52
36	Intrinsic resistance to PIM kinase inhibition in AML through p38Î±-mediated feedback activation of mTOR signaling. Oncotarget, 2016, 7, 37407-37419.	0.8	16

#	Article	IF	Citations
37	The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1. Scientific Reports, 2015, 5, 14798.	1.6	25
38	PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell Reports, 2015, 12, 1978-1985.	2.9	163
39	Identification of signalling cascades involved in red blood cell shrinkage and vesiculation. Bioscience Reports, 2015, 35, .	1.1	37
40	Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. Nucleic Acids Research, 2015, 43, 3407-3419.	6.5	124
41	SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer. Cell Research, 2015, 25, 445-458.	5.7	36
42	Parallel InÂVivo and InÂVitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition. Cell Reports, 2014, 9, 1375-1386.	2.9	34
43	The Good, the Bad, and the Ugly: in search of gold standards for assessing functional genetic screen quality. Molecular Systems Biology, 2014, 10, 738.	3.2	2
44	VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Research, 2014, 16, R53.	2.2	28
45	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508, 118-122.	13.7	702
46	Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15155-15160.	3.3	80
47	Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3. Cell Reports, 2014, 7, 86-93.	2.9	266
48	The Corepressor CTBP2 Is a Coactivator of Retinoic Acid Receptor/Retinoid X Receptor in Retinoic Acid Signaling. Molecular and Cellular Biology, 2013, 33, 3343-3353.	1.1	25
49	MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-Î² Receptor Signaling. Cell, 2012, 151, 937-950.	13.5	371
50	Identification of <scp>F</scp>â€box only protein 7 as a negative regulator of <scp>NF</scp>â€kappa<scp>B</scp> signalling. Journal of Cellular and Molecular Medicine, 2012, 16, 2140-2149.	1.6	38
51	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature, 2012, 483, 100-103.	13.7	1,769
52	Functional Subtyping of Breast Cancer. Cancer Discovery, 2011, 1, 205-206.	7.7	0
53	A Genome-wide Multidimensional RNAi Screen Reveals Pathways Controlling MHC Class II Antigen Presentation. Cell, 2011, 145, 268-283.	13.5	151
54	EGFR overexpression induces activation of telomerase via PI3K/AKTâ€mediated phosphorylation and transcriptional regulation through Hif1â€alpha in a cellular model of oralâ€“esophageal carcinogenesis. Cancer Science, 2011, 102, 351-360.	1.7	42

#	Article	IF	Citations
55	A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation. Journal of Experimental Medicine, 2011, 208, 2675-2689.	4.2	24
56	Screening for modulators of cisplatin sensitivity: Unbiased screens reveal common themes. Cell Cycle, 2011, 10, 380-386.	1.3	15
57	The Histone Demethylase Jarid1b (Kdm5b) Is a Novel Component of the Rb Pathway and Associates with E2f-Target Genes in MEFs during Senescence. PLoS ONE, 2011, 6, e25235.	1.1	44
58	Interleukin-1Râ€“Associated Kinase 2 Is a Novel Modulator of the Transforming Growth Factor Î² Signaling Cascade. Molecular Cancer Research, 2010, 8, 592-603.	1.5	3
59	Exploration of synthetic lethal interactions as cancer drug targets. Future Oncology, 2010, 6, 1789-1802.	1.1	14
60	Using large-scale RNAi screens to identify novel drug targets for cancer. IDrugs: the Investigational Drugs Journal, 2010, 13, 772-7.	0.7	5
61	Candidate Biomarkers of Response to an Experimental Cancer Drug Identified through a Large-scale RNA Interference Genetic Screen. Clinical Cancer Research, 2009, 15, 5811-5819.	3.2	9
62	Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma. Cancer Cell, 2009, 15, 67-78.	7.7	464
63	ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma Outcome. Cancer Cell, 2009, 15, 328-340.	7.7	132
64	Statistical methods for analysis of high-throughput RNA interference screens. Nature Methods, 2009, 6, 569-575.	9.0	532
65	A Large Scale shRNA Barcode Screen Identifies the Circadian Clock Component ARNTL as Putative Regulator of the p53 Tumor Suppressor Pathway. PLoS ONE, 2009, 4, e4798.	1.1	118
66	Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1. EMBO Journal, 2008, 27, 2851-2861.	3.5	70
67	Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235. Cancer Research, 2008, 68, 9221-9230.	0.4	474
68	The ubiquitin-specific protease USP28 is required for MYC stability. Nature Cell Biology, 2007, 9, 765-774.	4.6	391
69	Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature, 2007, 450, 725-730.	13.7	310
70	A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer. Cancer Cell, 2007, 12, 395-402.	7.7	1,471
71	An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nature Chemical Biology, 2006, 2, 202-206.	3.9	196
72	shRNA libraries and their use in cancer genetics. Nature Methods, 2006, 3, 701-706.	9.0	116

#	Article	IF	Citations
73	Telomerase-independent Regulation of ATR by Human Telomerase RNA. Journal of Biological Chemistry, 2006, 281, 40503-40514.	1.6	66
74	Differential transcriptional regulation of human telomerase in a cellular model representing important genetic alterations in esophageal squamous carcinogenesis. Carcinogenesis, 2005, 26, 1879-1889.	1.3	16
75	Involvement of MINK, a Ste20 Family Kinase, in Ras Oncogene-Induced Growth Arrest in Human Ovarian Surface Epithelial Cells. Molecular Cell, 2005, 20, 673-685.	4.5	96
76	A Genetic Screen Identifies PITX1 as a Suppressor of RAS Activity and Tumorigenicity. Cell, 2005, 121, 849-858.	13.5	257
77	A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature, 2004, 428, 431-437.	13.7	955
78	Inhibition of telomerase limits the growth of human cancer cells. Nature Medicine, 1999, 5, 1164-1170.	15.2	983
79	Creation of human tumour cells with defined genetic elements. Nature, 1999, 400, 464-468.	13.7	2,148
80	Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14723-14728.	3.3	582
81	hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization. Cell, 1997, 90, 785-795.	13.5	1,689
82	Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochimica Et Biophysica Acta: Reviews on Cancer, 1996, 1287, 103-120.	3.3	94
83	Functional Analysis of Burkitt's Lymphoma Mutant c-Myc Proteins. Journal of Biological Chemistry, 1996, 271, 5513-5518.	1.6	39
84	E2F-5, a New E2F Family Member That Interacts with p130 In Vivo. Molecular and Cellular Biology, 1995, 15, 3082-3089.	1.1	228
85	E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo.. Genes and Development, 1994, 8, 2680-2690.	2.7	312
86	Effects of Monomethylfumarate on Human Granulocytes. Journal of Investigative Dermatology, 1993, 101, 37-42.	0.3	59
87	Cloning, expression and chromosomal localization of a new putative receptor-like protein tyrosine phosphatase. FEBS Letters, 1991, 290, 123-130.	1.3	125
88	Bioassay development. , 0, , 67-84.		0